Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person TAM [nucleoplasm]

Class:Id	ChemicalDrug:9716874
_displayName	TAM [nucleoplasm]
_timestamp	2025-01-29 18:28:05
compartment	[Compartment:7660] nucleoplasm
created	[InstanceEdit:9716914] Jassal, Bijay, 2021-03-02
crossReference	[DatabaseIdentifier:9838653] ChEBI:41774
disease	[Disease:1500576] breast cancer [Disease:1500575] ovarian cancer
literatureReference	[LiteratureReference:9716909] Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta
modified	[InstanceEdit:9716963] Jassal, Bijay, 2021-03-02 [InstanceEdit:9730265] Jassal, Bijay, 2021-05-07 [InstanceEdit:9937076] D'Eustachio, Peter, 2025-01-29
name	TAM tamoxifen ICI-46474 Nolvadex® Soltamox®
referenceEntity	[ReferenceTherapeutic:9716923] tamoxifen [Guide to Pharmacology:1016]
stableIdentifier	[StableIdentifier:9716961] R-ALL-9716874.2
(hasMember)	[DefinedSet:9716906] ESR1 antagonists [nucleoplasm] [DefinedSet:9716925] ESR1 agonists [nucleoplasm]
(updatedInstance)	[_UpdateTracker:9940104] Update Tracker - [ChemicalDrug:9716874] TAM [nucleoplasm] - v92:[removeName]
[Change default viewing format]

No pathways have been reviewed or authored by TAM [nucleoplasm] (9716874)